IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v16y2025i1d10.1038_s41467-025-59168-5.html
   My bibliography  Save this article

Remdesivir, mAb114, REGN-EB3, and ZMapp partially rescue nonhuman primates infected with a low passage Kikwit variant of Ebola virus

Author

Listed:
  • Abhishek N. Prasad

    (University of Texas Medical Branch
    University of Texas Medical Branch)

  • Courtney Woolsey

    (University of Texas Medical Branch
    University of Texas Medical Branch)

  • Viktoriya Borisevich

    (University of Texas Medical Branch
    University of Texas Medical Branch)

  • Krystle N. Agans

    (University of Texas Medical Branch
    University of Texas Medical Branch)

  • Daniel J. Deer

    (University of Texas Medical Branch
    University of Texas Medical Branch)

  • Joan B. Geisbert

    (University of Texas Medical Branch
    University of Texas Medical Branch)

  • Mack B. Harrison

    (University of Texas Medical Branch
    University of Texas Medical Branch)

  • Natalie S. Dobias

    (University of Texas Medical Branch
    University of Texas Medical Branch)

  • Karla A. Fenton

    (University of Texas Medical Branch
    University of Texas Medical Branch)

  • Robert W. Cross

    (University of Texas Medical Branch
    University of Texas Medical Branch)

  • Thomas W. Geisbert

    (University of Texas Medical Branch
    University of Texas Medical Branch)

Abstract

In 2018, a clinical trial of four investigational therapies for Ebola virus disease (EVD), known as the PALM trial, was conducted in the Democratic Republic of Congo. All patients received either the antiviral remdesivir (RDV) or a monoclonal antibody product: ZMapp, mAb114 (Ebanga), or REGN-EB3 (Inmazeb). The study concluded that both mAb114 and REGN-EB3 were superior to ZMapp and RDV in reducing mortality from EVD. However, the data suggested that some patients in the RDV and ZMapp groups might have been sicker at the time of treatment initiation. Here, we assessed the efficacy of each of these therapies in a uniformly lethal rhesus monkey model of EVD when treatment was initiated 5 days after Ebola exposure. Treatment with RDV, mAb114, REGN-EB3, and ZMapp each resulted in similar survival (approximately 40%). Survival was associated with circulating viral load at treatment initiation. A trend of more escape mutants in the GP1 and GP2 domains was observed for the mAb114 group. Our data show similar suboptimal efficacy of individual therapeutics in the uniformly lethal NHP model of EVD, supporting further clinical investigation of therapeutic combinations to maximize the overall therapeutic effect and improve patient outcomes, particularly for the treatment of advanced stage EVD.

Suggested Citation

  • Abhishek N. Prasad & Courtney Woolsey & Viktoriya Borisevich & Krystle N. Agans & Daniel J. Deer & Joan B. Geisbert & Mack B. Harrison & Natalie S. Dobias & Karla A. Fenton & Robert W. Cross & Thomas , 2025. "Remdesivir, mAb114, REGN-EB3, and ZMapp partially rescue nonhuman primates infected with a low passage Kikwit variant of Ebola virus," Nature Communications, Nature, vol. 16(1), pages 1-13, December.
    • Handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-59168-5
    DOI: 10.1038/s41467-025-59168-5
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-025-59168-5
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-025-59168-5?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Robert W. Cross & Zachary A. Bornholdt & Abhishek N. Prasad & Joan B. Geisbert & Viktoriya Borisevich & Krystle N. Agans & Daniel J. Deer & Kevin Melody & Karla A. Fenton & Heinz Feldmann & Armand Spr, 2020. "Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment," Nature Communications, Nature, vol. 11(1), pages 1-8, December.
    2. Robert W. Cross & Zachary A. Bornholdt & Abhishek N. Prasad & Viktoriya Borisevich & Krystle N. Agans & Daniel J. Deer & Dafna M. Abelson & Do H. Kim & William S. Shestowsky & Lioudmila A. Campbell & , 2021. "Combination therapy protects macaques against advanced Marburg virus disease," Nature Communications, Nature, vol. 12(1), pages 1-10, December.
    3. Emily P. Thi & Chad E. Mire & Amy C. H. Lee & Joan B. Geisbert & Joy Z. Zhou & Krystle N. Agans & Nicholas M. Snead & Daniel J. Deer & Trisha R. Barnard & Karla A. Fenton & Ian MacLachlan & Thomas W. , 2015. "Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates," Nature, Nature, vol. 521(7552), pages 362-365, May.
    4. Jennifer M. Brannan & Shihua He & Katie A. Howell & Laura I. Prugar & Wenjun Zhu & Hong Vu & Sergey Shulenin & Shweta Kailasan & Henna Raina & Gary Wong & Md Niaz Rahim & Logan Banadyga & Kevin Tierne, 2019. "Post-exposure immunotherapy for two ebolaviruses and Marburg virus in nonhuman primates," Nature Communications, Nature, vol. 10(1), pages 1-10, December.
    5. Chad E. Mire & Demetrius Matassov & Joan B. Geisbert & Theresa E. Latham & Krystle N. Agans & Rong Xu & Ayuko Ota-Setlik & Michael A. Egan & Karla A. Fenton & David K. Clarke & John H. Eldridge & Thom, 2015. "Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus," Nature, Nature, vol. 520(7549), pages 688-691, April.
    6. Travis K. Warren & Robert Jordan & Michael K. Lo & Adrian S. Ray & Richard L. Mackman & Veronica Soloveva & Dustin Siegel & Michel Perron & Roy Bannister & Hon C. Hui & Nate Larson & Robert Strickley , 2016. "Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys," Nature, Nature, vol. 531(7594), pages 381-385, March.
    7. Xiangguo Qiu & Gary Wong & Jonathan Audet & Alexander Bello & Lisa Fernando & Judie B. Alimonti & Hugues Fausther-Bovendo & Haiyan Wei & Jenna Aviles & Ernie Hiatt & Ashley Johnson & Josh Morton & Kel, 2014. "Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp," Nature, Nature, vol. 514(7520), pages 47-53, October.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Surender Khurana & Gabrielle Grubbs & Supriya Ravichandran & Emily Cluff & JungHyun Kim & Ana I. Kuehne & Samantha Zak & John M. Dye & Julius J. Lutwama & Andrew S. Herbert, 2024. "Longitudinal proteome-wide antibody profiling in Marburg virus survivors identifies wing domain immunogen for vaccine design," Nature Communications, Nature, vol. 15(1), pages 1-15, December.
    2. Franziska K. Kaiser & Mariana Gonzalez Hernandez & Nadine Krüger & Ellinor Englund & Wenjuan Du & Anna Z. Mykytyn & Mathijs P. Raadsen & Mart M. Lamers & Francine Rodrigues Ianiski & Tatiana M. Shamor, 2024. "Filamentous fungus-produced human monoclonal antibody provides protection against SARS-CoV-2 in hamster and non-human primate models," Nature Communications, Nature, vol. 15(1), pages 1-14, December.
    3. Ropo E. Ogunsakin & Oluwakemi Ebenezer & Maryam A. Jordaan & Michael Shapi & Themba G. Ginindza, 2022. "Mapping Scientific Productivity Trends and Hotspots in Remdesivir Research Publications: A Bibliometric Study from 2016 to 2021," IJERPH, MDPI, vol. 19(14), pages 1-22, July.
    4. Zhang, Kebo & Hong, Xiao & Han, Yuexing & Wang, Bing, 2023. "Optimal discrete resource allocation on metapopulation networks for suppressing spatial spread of epidemic," Chaos, Solitons & Fractals, Elsevier, vol. 169(C).
    5. Wataru Nishi & Ei Wakamatsu & Hiroaki Machiyama & Ryohei Matsushima & Kensho Saito & Yosuke Yoshida & Tetsushi Nishikawa & Tomohiro Takehara & Hiroko Toyota & Masae Furuhata & Hitoshi Nishijima & Arat, 2023. "Evaluation of therapeutic PD-1 antibodies by an advanced single-molecule imaging system detecting human PD-1 microclusters," Nature Communications, Nature, vol. 14(1), pages 1-16, December.
    6. Farah Daou & Gretta Abou-Sleymane & Danielle A. Badro & Nagham Khanafer & Mansour Tobaiqy & Achraf Al Faraj, 2021. "The History, Efficacy, and Safety of Potential Therapeutics: A Narrative Overview of the Complex Life of COVID-19," IJERPH, MDPI, vol. 18(3), pages 1-16, January.
    7. Katja Voit & Cristian Timmermann & Florian Steger, 2021. "Medication of Hydroxychloroquine, Remdesivir and Convalescent Plasma during the COVID-19 Pandemic in Germany—An Ethical Analysis," IJERPH, MDPI, vol. 18(11), pages 1-16, May.
    8. Jade Mitchell & Kara Dean & Charles Haas, 2020. "Ebola Virus Dose Response Model for Aerosolized Exposures: Insights from Primate Data," Risk Analysis, John Wiley & Sons, vol. 40(11), pages 2390-2398, November.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-59168-5. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.